| Literature DB >> 33614740 |
Yuling Wu1,2, Nana Pan2, Yi An2, Mengyuan Xu2, Lijuan Tan2, Lijuan Zhang1.
Abstract
The incidence of myocardial infarction (MI) increases every year worldwide. Better diagnostic and prognostic biomarkers for clinical applications are the consistent pursuit of MI research. In addition to electrocardiogram, echocardiography, coronary angiography, etc., circulating biomarkers are essential for the diagnosis, prognosis, and treatment effect monitoring of MI patients. In this review, we assessed both strength and weakness of MI circulating biomarkers including: (1) originated from damaged myocardial tissues including current golden standard cardiac troponin, (2) released from non-myocardial tissues due to MI-induced systems reactions, and (3) preexisted in blood circulation before the occurrence of MI event. We also summarized newly reported MI biomarkers. We proposed that the biomarkers preexisting in blood circulation before MI incidents should be emphasized in research and development for MI prevention in near future.Entities:
Keywords: MI diagnosis; MI prognosis; circulating biomarkers; myocardial infarction; serum biomarkers
Year: 2021 PMID: 33614740 PMCID: PMC7886815 DOI: 10.3389/fcvm.2020.617277
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X